Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis
Ann-Marie Mallon,Dieter A. Häring,Frank Dahlke,Piet Aarden,Soroosh Afyouni,Daniel Delbarre,Khaled El Emam,Habib Ganjgahi,Stephen Gardiner,Chun Hei Kwok,Dominique M. West,Ewan Straiton,Sibylle Haemmerle,Adam Huffman,Tom Hofmann,Luke J. Kelly,Peter Krusche,Marie-Claude Laramee,Karine Lheritier,Greg Ligozio,Aimee Readie,Luis Santos,Thomas E. Nichols,Janice Branson,Chris Holmes
DOI: https://doi.org/10.1186/s12874-021-01409-4
2021-11-14
BMC Medical Research Methodology
Abstract:Abstract Background Novartis and the University of Oxford’s Big Data Institute (BDI) have established a research alliance with the aim to improve health care and drug development by making it more efficient and targeted. Using a combination of the latest statistical machine learning technology with an innovative IT platform developed to manage large volumes of anonymised data from numerous data sources and types we plan to identify novel patterns with clinical relevance which cannot be detected by humans alone to identify phenotypes and early predictors of patient disease activity and progression. Method The collaboration focuses on highly complex autoimmune diseases and develops a computational framework to assemble a research-ready dataset across numerous modalities. For the Multiple Sclerosis (MS) project, the collaboration has anonymised and integrated phase II to phase IV clinical and imaging trial data from ≈35,000 patients across all clinical phenotypes and collected in more than 2200 centres worldwide. For the “IL-17” project, the collaboration has anonymised and integrated clinical and imaging data from over 30 phase II and III Cosentyx clinical trials including more than 15,000 patients, suffering from four autoimmune disorders (Psoriasis, Axial Spondyloarthritis, Psoriatic arthritis (PsA) and Rheumatoid arthritis (RA)). Results A fundamental component of successful data analysis and the collaborative development of novel machine learning methods on these rich data sets has been the construction of a research informatics framework that can capture the data at regular intervals where images could be anonymised and integrated with the de-identified clinical data, quality controlled and compiled into a research-ready relational database which would then be available to multi-disciplinary analysts. The collaborative development from a group of software developers, data wranglers, statisticians, clinicians, and domain scientists across both organisations has been key. This framework is innovative, as it facilitates collaborative data management and makes a complicated clinical trial data set from a pharmaceutical company available to academic researchers who become associated with the project. Conclusions An informatics framework has been developed to capture clinical trial data into a pipeline of anonymisation, quality control, data exploration, and subsequent integration into a database. Establishing this framework has been integral to the development of analytical tools.
health care sciences & services